Latest Articles

Publication Date
Sequencing Radiation With Systemic Therapy in Inoperable Endometrial Cancer - CancerNetwork

Sequencing Radiation With Systemic Therapy in Inoperable Endometrial Cancer CancerNetwork

Published: Feb. 21, 2026, 2:18 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Advance Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer - Femtech Insider

Sensei Biotherapeutics Acquires Faeth Therapeutics in $200M Deal, Advancing Multi-Node Cancer Therapy for Endometrial and Breast Cancer Femtech Insider

Published: Feb. 18, 2026, 3:28 p.m.
Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... - Medical Dialogues

Adding GLP-1RA to Progestin Therapy may reduce Endometrial Cancer Risk among women with benign uterine... Medical Dialogues

Published: Feb. 17, 2026, 3:15 p.m.
Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk - geneonline.com

Study Finds GLP-1 Medications Combined with Progestin Therapy May Lower Endometrial Cancer Risk geneonline.com

Published: Feb. 16, 2026, 6:10 a.m.
Cervical, endometrial and urothelial cancers, how immunotherapy changes treatment strategies - Il Sole 24 ORE

Cervical, endometrial and urothelial cancers, how immunotherapy changes treatment strategies Il Sole 24 ORE

Published: Feb. 5, 2026, 10:31 a.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Yahoo Finance Singapore

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Yahoo …

Published: Feb. 3, 2026, 1 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!